Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!

ImmuneRegen will use Mission3 OnDemand as its technology infrastructure to manage and drive its product candidates through the development process and complete the regulatory submission life cycle.

Mission3 OnDemand integrates project, document, and regulatory submission management into one simple to use, easy to deploy, web-based software suite that Life Sciences companies use to manage the development of product candidates from post discovery through regulatory submission.

“We are excited to be working with a strong, growing company like ImmuneRegen. Given the nature of today’s industry, outsourcing plays a key role. Mission3 OnDemand provides ImmuneRegen with a secure, central collaboration platform where people outside their organization can contribute to research and product development effectively”, said Dirk Karsten Beth, President and Founder of Mission3.

Mission3 OnDemand organizes documents based on project structure, rather than in an arbitrary folder structure. Projects are dynamically tied to documents and as documentation is completed, real-time updates in project status are provided. Additionally, the documentation follows all ICH regulatory guidelines and flows seamlessly into corresponding regulatory submissions that can be electronically submitted and managed.

“After a thorough review of the products on the market, we chose Mission3 OnDemand because it offers the best technology and value for a company like ours,” said Michael Wilhelm, CEO of ImmuneRegen. “It was easy to setup and deploy and I can dynamically track projects with our labs and CROs. Real-time information is at my fingertips and quickly retrievable, whether I’m in the office, at home or traveling to visit with investors and analysts. Our scientists appreciate the version controls as well as its availability and security when dealing with different laboratories and vendors.”

About ImmuneRegen BioSciences, Inc.
IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., (immuneregen.com) is a development stage biotechnology company focused on the research and development of Homspera™ and its derivatives Radilex® and Viprovex®, which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera™ is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system.

About Mission3, Inc.
Mission3 (mission3.com) is a leading provider of product lifecycle management software that specifically serves the unique needs of the Life Sciences industry. Mission3 OnDemand is a fully integrated, CFR 21 Part 11 compliant, Document, Project, and Regulatory Submission Management suite that is truly web-based and offered in an on-demand (SaaS) environment. It merges cutting edge technology with affordability, exclusively for Life Sciences Organizations. Designed for rapid deployment and ease of use, Mission3 OnDemand suite manages all documents within business areas governed by world wide regulatory bodies and corresponding submissions.

PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Mission3 securities in any jurisdiction including any other companies listed or named in this release.